share_log

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Apr 16 15:41
Summary by Moomoo AI
Cybin Inc., a clinical-stage biopharmaceutical company, announced on April 16, 2024, that the United States Patent and Trademark Office has granted it a U.S. patent (11,958,807) for its CYB003 program, aimed at treating Major Depressive Disorder (MDD). The patent, which is expected to provide exclusivity until at least 2041, covers pharmaceutical compositions within Cybin's proprietary deuterated psilocybin analog program. The company's patent portfolio now includes over 50 granted patents and more than 170 pending applications. Cybin's CEO, Doug Drysdale, highlighted the importance of this patent in protecting their intellectual property and advancing the CYB003 program. The company has also received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for CYB003, which supports a faster regulatory pathway. Cybin plans to begin enrollment for a multinational, multisite Phase 3 program evaluating CYB003 around mid-year 2024. Cybin is focused on developing psychedelic-based therapeutics for mental health conditions and is operational in multiple countries.
Cybin Inc., a clinical-stage biopharmaceutical company, announced on April 16, 2024, that the United States Patent and Trademark Office has granted it a U.S. patent (11,958,807) for its CYB003 program, aimed at treating Major Depressive Disorder (MDD). The patent, which is expected to provide exclusivity until at least 2041, covers pharmaceutical compositions within Cybin's proprietary deuterated psilocybin analog program. The company's patent portfolio now includes over 50 granted patents and more than 170 pending applications. Cybin's CEO, Doug Drysdale, highlighted the importance of this patent in protecting their intellectual property and advancing the CYB003 program. The company has also received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for CYB003, which supports a faster regulatory pathway. Cybin plans to begin enrollment for a multinational, multisite Phase 3 program evaluating CYB003 around mid-year 2024. Cybin is focused on developing psychedelic-based therapeutics for mental health conditions and is operational in multiple countries.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more